Showing results (451-460 of 14,086) with videos related to

Sort By:
Pageof 1,409
Gynecologic Oncology|May 14, 2020
Knowledge of endometrial cancer risk factors in a general gynecologic populationChristina R Washington, Ashley Haggerty, Wanda Ronner, et al.
Gynecologic Oncology|May 14, 2020
Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort studyFernanda Freitas, Antonio Braga, Mauricio Viggiano, et al.
Gynecologic Oncology|May 14, 2020
Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomesKoji Matsuo, Erica J Chang, Shinya Matsuzaki, et al.
Gynecologic Oncology|December 31, 1997
Radiotherapy for centrally recurrent cervical cancer of the vaginal stump following hysterectomyH Ito, N Shigematsu, T Kawada, et al.
Gynecologic Oncology|April 30, 2020
Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosisGemma Searle, Rachel Pounds, Andrew Phillips, et al.
Gynecologic Oncology|April 9, 2020
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effectRebecca C Arend, Hannah M Beer, Yael C Cohen, et al.
Gynecologic Oncology|October 27, 2019
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG studyRoisin E O'Cearbhaill, Wei Deng, Lee-May Chen, et al.
Gynecologic Oncology|May 16, 2021
Decreasing utilization of minimally invasive hysterectomy for cervical cancer in the United StatesKoji Matsuo, Rachel S Mandelbaum, Maximilian Klar, et al.
Gynecologic Oncology|August 22, 2021
Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trialMathew Cowan, Wendy M Swetzig, Valery Adorno-Cruz, et al.
Gynecologic Oncology|August 28, 2021
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivoJoan Tymon-Rosario, Elena Bonazzoli, Stefania Bellone, et al.
Pageof 1,409